- IP to Startups
- Biomedical Research Cores
Rutgers Partners with Horizon Discovery to Develop a New Gene Editing Technology
By: Chris Perkins
Published: January 28, 2019
Rutgers University has partnered with Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, to develop a new technique built on CRISPR.
Originally developed by Shengkan "Victor" Jin, associate professor of pharmacology in the Robert Wood Johnson Medical School at Rutgers, and Juan Carlos Collantes, currently a pharmacology postdoctoral fellow, the technique allows for safer and more effective gene editing than existing CRISPR methods, and has the potential to develop new therapies for sickle cell anemia, HIV, leukemia and more.
Part of this project's funding came from the TechAdvance Fund, an early-stage-technology fund that provides financial support and business expertise for Rutgers faculty and students to advance promising technologies toward commercialization.
To view the full press release, visit the source link below.
Source: ORED News Page.
Header image couresy of Wikipedia